Merck (MRK)

Merck recently informed its partner Arena Pharmaceuticals that it was pulling out of a collaboration agreement pertaining to the development of an atherosclerosis drug.
The decision by Merck to discontinue the development of the candidate, MK-1903, a niacin receptor agonist for treating atherosclerosis, followed disappointing results from a recently completed mid-stage study.

Dec 29 · 2:31:00 PM · Source: Benzinga · Related: Arena Pharmaceuticals Inc.
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto